Can Rituximab cause serum sickness in patients with immune thrombocytopenia?
Rituximab is a monoclonal antibody used as a second-line treatment for immune thrombocytopenia (ITP). Serum sickness is a delayed hypersensitivity reaction that can occur after rituximab exposure. In patients with ITP, this complication has been reported, though it appears to be uncommon. Symptoms typically include joint pain, fever, and rash, and may develop days after the infusion.
What the research says
A systematic review of published case reports found that rituximab-induced serum sickness (RISS) occurred in patients with various conditions, including immune thrombocytopenia, which accounted for 20.5% of cases 1. The median onset of symptoms was 7 days after the last rituximab dose, with common symptoms being joint pain (92.3%), fever (82.1%), and rash (66.7%) 1. Anti-rituximab antibodies were detected in 90.9% of tested cases, suggesting an immune-mediated mechanism 1.
In children with ITP, the incidence of serum sickness may be higher than in adults, according to a 2010 review 5. A prospective registry of 248 adults with ITP treated with rituximab did not specifically report serum sickness, but noted that rituximab was generally well-tolerated over long-term follow-up 6. A case report described a young adult with Evans syndrome (which includes ITP) who developed serum sickness, acute respiratory distress syndrome, and platelet refractoriness after rituximab, attributed to neutralizing antibodies 7. The patient was successfully treated with obinutuzumab, a different anti-CD20 antibody 7.
Overall, while rituximab-induced serum sickness is a recognized complication in ITP, it appears to be rare. The evidence comes from case reports and series, not large controlled trials, so the exact frequency is not well established.
What to ask your doctor
- What are the signs of serum sickness I should watch for after rituximab treatment?
- If I develop serum sickness, what treatment options are available?
- Are there alternative treatments to rituximab that might have a lower risk of serum sickness?
- Should I be tested for anti-rituximab antibodies if I have a reaction?
- How does the risk of serum sickness compare between rituximab and other ITP treatments?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.